Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123062 | 0.93 | OPRM1 (0.48) | OPRM1XIAPOPRD1OPRK1DPP4 | |
| SCHEMBL29644398 | 0.92 | OPRM1 (0.48) | OPRM1CAPN1OPRD1OPRK1 | |
| SCHEMBL30775496 | 0.92 | OPRM1 (0.54) | OPRM1XIAPCAPN1OPRD1OPRK1 | |
| SCHEMBL29811183 | 0.91 | OPRM1 (0.49) | OPRM1XIAPCAPN1OPRD1OPRK1 | |
| SCHEMBL29641641 | 0.91 | OPRM1 (0.51) | OPRM1XIAPOPRD1OPRK1DPP4 | |
| SCHEMBL31383711 | 0.90 | OPRM1 (0.50) | OPRM1XIAPCAPN1OPRD1OPRK1 | |
| SCHEMBL29360690 | 0.90 | OPRM1 (0.45) | OPRM1XIAPCAPN1OPRD1OPRK1 | |
| SCHEMBL30222712 | 0.89 | OPRM1 (0.46) | OPRM1XIAPOPRD1OPRK1 | |
| SCHEMBL29351176 | 0.87 | OPRM1 (0.51) | OPRM1XIAPCAPN1OPRD1OPRK1 | |
| SCHEMBL30314935 | 0.87 | KMT2A (0.48) | OPRM1XIAPCAPN1CTSBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4241785-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-01 | — | — | US | disclosed |
| CN-120037261-A | Targeting therapeutic pharmaceutical composition based on coupling of immune cells and small molecular peptides | 北京钦川科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4241785-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116162175-A | Influenza virus vaccine and application thereof | 西奈山伊坎医学院 | 2023-05-26 | — | — | CN | disclosed |
| EP-2758075-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | CD44, SIGLEC7, SIGLEC9 | OPRM1 1658/4885XIAP 4484/4885CAPN1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.